Immunocore Holdings plc Foreign Currency Transaction Gain (Loss), Unrealized
Immunocore Holdings plc (IMCR) reported Foreign Currency Transaction Gain (Loss), Unrealized of $2.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-08-06
- Immunocore Holdings plc foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was -$808.00K.
- Immunocore Holdings plc foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was $3.49M, a 20.06% increase year-over-year.
- Immunocore Holdings plc foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was -$3.84M.
- Immunocore Holdings plc foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was $9.62M, a 78.65% increase year-over-year.
- Immunocore Holdings plc foreign currency transaction gain (loss), unrealized for fiscal 2025 was $6.38M.
- Immunocore Holdings plc foreign currency transaction gain (loss), unrealized for fiscal 2024 was -$599.00K.
- Immunocore Holdings plc foreign currency transaction gain (loss), unrealized for fiscal 2023 was -$13.83M, a 195.48% decline from fiscal 2022.
- Immunocore Holdings plc foreign currency transaction gain (loss), unrealized for fiscal 2022 was $14.48M.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$808.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.68M 10-Q · filed 2026-08-06 | -$1.16M derived: sum of 3 quarters · filed 2026-08-06 | $8.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.49M 10-Q · filed 2026-05-06 | -$354.00K derived: sum of 2 quarters · filed 2026-05-06 | $9.27M derived: sum of 3 quarters · filed 2026-05-06 | $6.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.78M derived: sum of 2 quarters · filed 2026-02-25 | $3.48M derived: sum of 3 quarters · filed 2026-08-06 | $6.38M 10-K · filed 2026-02-25 |
| 2025-09-30 | $9.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $7.32M derived: sum of 2 quarters · filed 2026-08-06 | $10.23M 10-Q · filed 2025-11-06 | $5.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $607.00K 10-Q · filed 2026-08-06 | -$3.97M derived: sum of 3 quarters · filed 2026-08-06 | $1.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.91M 10-Q · filed 2026-05-06 | -$1.67M derived: sum of 2 quarters · filed 2026-05-06 | $3.71M derived: sum of 3 quarters · filed 2026-05-06 | $3.61M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $805.00K derived: sum of 2 quarters · filed 2026-02-25 | $705.00K derived: sum of 3 quarters · filed 2026-02-25 | -$599.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.29M derived: sum of 2 quarters · filed 2025-11-06 | $3.98M 10-Q · filed 2025-11-06 | -$9.85M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.40M 10-Q · filed 2025-08-07 | -$15.24M derived: sum of 3 quarters · filed 2026-02-25 | -$3.79M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$1.30M 10-Q · filed 2025-05-07 | -$15.14M derived: sum of 2 quarters · filed 2026-02-25 | -$3.69M derived: sum of 3 quarters · filed 2026-02-25 | -$7.92M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$13.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$2.38M derived: sum of 2 quarters · filed 2026-02-25 | -$6.62M derived: sum of 3 quarters · filed 2026-02-25 | -$13.83M 10-K · filed 2026-02-25 |
| 2023-09-30 | $11.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $7.22M derived: sum of 2 quarters · filed 2024-11-06 | $9.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$11.44M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$7.21M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $14.48M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$99.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |